From the Best of TSC TV: Portfolio manager David Peltier discusses two inexpensive stocks that appear attractive at current levels. Original air date: 12/01/09
12:00PM 12/06/09
Genzyme Resumes Some Shipments At Mass. Facility
Genzyme says it resumed shipping after plant shutdown, but reports delays in making Fabrazyme
04:53PM 12/01/09
Stocks Under $10: 2 Potential Buys
Portfolio Manager David Peltier discusses two low-dollar that appear attractive at current levels.
01:46PM 12/01/09
Protalix-Pfizer Tag Team Against Genzyme: BioBuzz
New partnership for Gaucher's drug takes aim at Genzyme.
10:09AM 12/01/09
Weatherford Director Buys $1.6M
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
10:09AM 11/27/09
Biotech Stock Mailbag: Targacept
Targacept's depression drug TC-5214 makes it a great candidate to land a lucrative partnership from Big Pharma.
06:00AM 11/27/09
Here's what some of our market pros are saying and playing.
03:40PM 11/23/09
Biotech Stock Mailbag: FDA Playbook
Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process.
06:01AM 11/20/09
Another Genzyme Drug Goes Kaboom: BioBuzz
Company halts development of kidney disease drug following poor test results.
08:05AM 11/18/09
Genzyme Ends Development Of Renvela Successor
Genzyme says new kidney drug met goals but did not work better than Renvela in clinical trial
07:30AM 11/18/09
Genzyme's Termeer: Worst Biotech CEO of '09
Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009.
12:31PM 11/17/09
Isis Cholesterol Drug Effective, but Safety a Worry: BioBuzz
Mipomersen lowers cholesterol but not without liver side effects.
10:56AM 11/17/09



Connect with TheStreet